Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (27947)	2/7/1999 7:52:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Here's what the San Diego Union Tribune had to say about ONTAK approval: biocognizance.com

To: RXGOLF who wrote (27947)	2/7/1999 12:27:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Here's a recent report (in a peer reviewed journal) indicating that ONTAK (DAB389IL-2) specificity can be improved by pre-treating with IL-1 alpha: J Clin Immunol 1998 May;18(3):223-34 Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes. Salard D, Kuzel TM, Samuelson E, Rosen S, Bakouche O Department of Molecular Pharmacology and Biological Chemistry, Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA. DAB389IL-2 is a recombinant fusion toxin composed of the diphtheria A chain and a protion of the translocating region of the diphtheria B chain, replacing the receptor binding domain with human IL-2. DAB389IL-2 can be safely administered to humans with mycosis fungoides (MF) or Sezary syndrome (SS), and antineoplastic effects occur. This agent binds optimally to the high-affinity IL-2R. The decreased efficiency of uptake by neoplastic cells which do not express the high-affinity IL-2R represents a potential limitation. Treatment of the HUT-78 cutaneous T-cell lymphoma with IL-1 alpha preceding exposure to DAB389IL-2 overcame their resistance to the toxin, IL-1 alpha inducing high-affinity IL-2R expression. Similarly, pretreatment with IL-1 alpha of SS patient lymphocytes demonstrated increased cytotoxicity compared to treatment with the fusion toxin alone. Normal lymphocytes and monocytes were not sensitive to DAB389IL-2 when pretreated with IL-1 alpha, suggesting a differential sensitivity which may be exploited clinically in the treatment of lymphomas. PMID: 9624582, UI: 98287678